These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 35064805)

  • 21. Ultrafast DCE-MRI for discriminating pregnancy-associated breast cancer lesions from lactation related background parenchymal enhancement.
    Nissan N; Anaby D; Mahameed G; Bauer E; Moss Massasa EE; Menes T; Agassi R; Brodsky A; Grimm R; Nickel MD; Roccia E; Sklair-Levy M
    Eur Radiol; 2023 Nov; 33(11):8122-8131. PubMed ID: 37278853
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Value of ultrafast and standard dynamic contrast-enhanced magnetic resonance imaging in the evaluation of the presence and extension of residual disease after neoadjuvant chemotherapy in breast cancer.
    Kato E; Mori N; Mugikura S; Sato S; Ishida T; Takase K
    Jpn J Radiol; 2021 Aug; 39(8):791-801. PubMed ID: 33743147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonmass Enhancement Breast Lesions: Diagnostic Performance of Kinetic Assessment on Ultrafast and Standard Dynamic Contrast-Enhanced MRI in Comparison With Morphologic Evaluation.
    Mori N; Sheth D; Abe H
    AJR Am J Roentgenol; 2020 Aug; 215(2):511-518. PubMed ID: 32452698
    [No Abstract]   [Full Text] [Related]  

  • 24. Exploring the added value of pretherapeutic MR descriptors in predicting breast cancer pathologic complete response to neoadjuvant chemotherapy.
    Malhaire C; Selhane F; Saint-Martin MJ; Cockenpot V; Akl P; Laas E; Bellesoeur A; Ala Eddine C; Bereby-Kahane M; Manceau J; Sebbag-Sfez D; Pierga JY; Reyal F; Vincent-Salomon A; Brisse H; Frouin F
    Eur Radiol; 2023 Nov; 33(11):8142-8154. PubMed ID: 37318605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC).
    Abdelhafez AH; Musall BC; Adrada BE; Hess K; Son JB; Hwang KP; Candelaria RP; Santiago L; Whitman GJ; Le-Petross HT; Moseley TW; Arribas E; Lane DL; Scoggins ME; Leung JWT; Mahmoud HS; White JB; Ravenberg EE; Litton JK; Valero V; Wei P; Thompson AM; Moulder SL; Pagel MD; Ma J; Yang WT; Rauch GM
    Breast Cancer Res Treat; 2021 Jan; 185(1):1-12. PubMed ID: 32920733
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative DCE-MRI for prediction of pathological complete response following neoadjuvant treatment for locally advanced breast cancer: the impact of breast cancer subtypes on the diagnostic accuracy.
    Drisis S; Metens T; Ignatiadis M; Stathopoulos K; Chao SL; Lemort M
    Eur Radiol; 2016 May; 26(5):1474-84. PubMed ID: 26310583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Features from Computerized Texture Analysis of Breast Cancers at Pretreatment MR Imaging Are Associated with Response to Neoadjuvant Chemotherapy.
    Chamming's F; Ueno Y; Ferré R; Kao E; Jannot AS; Chong J; Omeroglu A; Mesurolle B; Reinhold C; Gallix B
    Radiology; 2018 Feb; 286(2):412-420. PubMed ID: 28980886
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differences Between Ipsilateral and Contralateral Early Parenchymal Enhancement Kinetics Predict Response of Breast Cancer to Neoadjuvant Therapy.
    Ren Z; Pineda FD; Howard FM; Hill E; Szasz T; Safi R; Medved M; Nanda R; Yankeelov TE; Abe H; Karczmar GS
    Acad Radiol; 2022 Oct; 29(10):1469-1479. PubMed ID: 35351365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
    Gampenrieder SP; Peer A; Weismann C; Meissnitzer M; Rinnerthaler G; Webhofer J; Westphal T; Riedmann M; Meissnitzer T; Egger H; Klaassen Federspiel F; Reitsamer R; Hauser-Kronberger C; Stering K; Hergan K; Mlineritsch B; Greil R
    Breast Cancer Res; 2019 Jan; 21(1):19. PubMed ID: 30704493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can imaging kinetic parameters of dynamic contrast-enhanced magnetic resonance imaging be valuable in predicting clinicopathological prognostic factors of invasive breast cancer?
    Wang C; Wei W; Santiago L; Whitman G; Dogan B
    Acta Radiol; 2018 Jul; 59(7):813-821. PubMed ID: 29105486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maximum slope using ultrafast breast DCE-MRI at 1.5 Tesla: a potential tool for predicting breast lesion aggressiveness.
    Pelissier M; Ambarki K; Salleron J; Henrot P
    Eur Radiol; 2021 Dec; 31(12):9556-9566. PubMed ID: 34117556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early assessment of breast cancer response to neoadjuvant chemotherapy by semi-quantitative analysis of high-temporal resolution DCE-MRI: preliminary results.
    Abramson RG; Li X; Hoyt TL; Su PF; Arlinghaus LR; Wilson KJ; Abramson VG; Chakravarthy AB; Yankeelov TE
    Magn Reson Imaging; 2013 Nov; 31(9):1457-64. PubMed ID: 23954320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic performance of maximum slope: A kinetic parameter obtained from ultrafast dynamic contrast-enhanced magnetic resonance imaging of the breast using k-space weighted image contrast (KWIC).
    Ohashi A; Kataoka M; Kanao S; Iima M; Murata K; Weiland E; Onishi N; Kawai M; Toi M; Togashi K
    Eur J Radiol; 2019 Sep; 118():285-292. PubMed ID: 31324411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the Tumor Response After Neoadjuvant Chemotherapy in Breast Cancer Patients: Correlation Between Dynamic Contrast-enhanced Magnetic Resonance Imaging and Pathologic Tumor Cellularity.
    Choi WJ; Kim WK; Shin HJ; Cha JH; Chae EY; Kim HH
    Clin Breast Cancer; 2018 Feb; 18(1):e115-e121. PubMed ID: 28890184
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dynamic breast magnetic resonance imaging: pretreatment prediction of tumor response to neoadjuvant chemotherapy.
    Dongfeng H; Daqing M; Erhu J
    Clin Breast Cancer; 2012 Apr; 12(2):94-101. PubMed ID: 22169574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maximum slope of ultrafast dynamic contrast-enhanced MRI of the breast: Comparisons with prognostic factors of breast cancer.
    Yamaguchi K; Nakazono T; Egashira R; Fukui S; Baba K; Hamamoto T; Irie H
    Jpn J Radiol; 2021 Mar; 39(3):246-253. PubMed ID: 33001328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of pathological complete response after neoadjuvant systemic treatment of invasive breast cancer using diffusion-weighted imaging compared with dynamic contrast-enhanced based kinetic analysis.
    Ota R; Kataoka M; Iima M; Honda M; Ohashi A; Ohno Kishimoto A; Miyake KK; Yamada Y; Takeuchi Y; Toi M; Nakamoto Y
    Eur J Radiol; 2022 Sep; 154():110372. PubMed ID: 35667297
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Pathologic Response Evaluation Systems After Neoadjuvant Chemotherapy in Breast Cancers: Correlation With Computer-Aided Diagnosis of MRI Features.
    Choi WJ; Kim HH; Cha JH; Shin HJ; Chae EY
    AJR Am J Roentgenol; 2019 Oct; 213(4):944-952. PubMed ID: 31237439
    [No Abstract]   [Full Text] [Related]  

  • 39. Ultrafast Dynamic Contrast-enhanced MRI of the Breast: How Is It Used?
    Kataoka M; Honda M; Ohashi A; Yamaguchi K; Mori N; Goto M; Fujioka T; Mori M; Kato Y; Satake H; Iima M; Kubota K
    Magn Reson Med Sci; 2022 Mar; 21(1):83-94. PubMed ID: 35228489
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ultrafast Dynamic Contrast-Enhanced MRI of the Breast: From Theory to Practice.
    Kataoka M; Honda M; Sagawa H; Ohashi A; Sakaguchi R; Hashimoto H; Iima M; Takada M; Nakamoto Y
    J Magn Reson Imaging; 2024 Aug; 60(2):401-416. PubMed ID: 38085134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.